Cargando…

A minimally-edited mouse model for infection with multiple SARS-CoV-2 strains

Efficient mouse models to study SARS-CoV-2 infection are critical for the development and assessment of vaccines and therapeutic approaches to mitigate the current pandemic and prevent reemergence of COVID-19. While the first generation of mouse models allowed SARS-CoV-2 infection and pathogenesis,...

Descripción completa

Detalles Bibliográficos
Autores principales: Nakandakari-Higa, Sandra, Parsa, Roham, Reis, Bernardo S., de Carvalho, Renan V. H., Mesin, Luka, Hoffmann, Hans-Heinrich, Bortolatto, Juliana, Muramatsu, Hiromi, Lin, Paulo. J. C., Bilate, Angelina M., Rice, Charles M., Pardi, Norbert, Mucida, Daniel, Victora, Gabriel D., Canesso, Maria Cecilia C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9703079/
https://www.ncbi.nlm.nih.gov/pubmed/36451809
http://dx.doi.org/10.3389/fimmu.2022.1007080
Descripción
Sumario:Efficient mouse models to study SARS-CoV-2 infection are critical for the development and assessment of vaccines and therapeutic approaches to mitigate the current pandemic and prevent reemergence of COVID-19. While the first generation of mouse models allowed SARS-CoV-2 infection and pathogenesis, they relied on ectopic expression and non-physiological levels of human angiotensin-converting enzyme 2 (hACE2). Here we generated a mouse model carrying the minimal set of modifications necessary for productive infection with multiple strains of SARS-CoV-2. Substitution of only three amino acids in the otherwise native mouse Ace2 locus (Ace2 (TripleMutant) or Ace2™), was sufficient to render mice susceptible to both SARS-CoV-2 strains USA-WA1/2020 and B.1.1.529 (Omicron). Infected Ace2™ mice exhibited weight loss and lung damage and inflammation, similar to COVID-19 patients. Previous exposure to USA-WA1/2020 or mRNA vaccination generated memory B cells that participated in plasmablast responses during breakthrough B.1.1.529 infection. Thus, the Ace2™ mouse replicates human disease after SARS-CoV-2 infection and provides a tool to study immune responses to sequential infections in mice.